Medtide Inc. (Stock Code: 3880.HK) is a peptide-focused contract research, development, and manufacturing organization (CRDMO), offering full-cycle services ranging from early-stage discovery, pre-clinical research and clinical development to commercial-stage production. The company is headquartered in Hangzhou, China, and has commercial production bases and offices in both China and the United States. We have been deeply involved in the peptide field for over 25 years. Today, we have become a CRDMO with global operations and comprehensive service capabilities.

Medtide Inc. provides (i) contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis; and (ii) contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing and controls (CMC) development and commercial manufacturing. We have established global operations, with projects covering over 50 countries, including major markets such as China, the United States, Japan, Europe, South Korea, and Australia. We provide our 1000+ customers with peptide drug development, production, and CMC documentation and filing support services that meet regulatory requirements in major markets worldwide.

Medtide Inc.

Org chart

Teams

Offices

Medtide Inc.

Org chart

Teams

Offices

Related companies